Blog

Sedana Medical (OM:SEDANA) remains unprofitable, posting losses that have increased at 1% per year over the past five years. Looking ahead, the company is forecast to stay in the red for at least the next three years. Revenue is projected to grow by 26.45% per year, outpacing the broader Swedish market’s 3.9% expected annual growth. Investors are weighing this robust revenue outlook against the risk backdrop of continued losses and an uncertain path to profitability.

See our full analysis for Sedana Medical.

With the numbers in, the next section will compare Sedana Medical’s latest results to the key narratives shaping market sentiment. We will see where the data strengthens consensus and where it forces a rethink.

See what the community is saying about Sedana Medical

• Sedana Medical’s future gross margin outlook benefits from operational improvements. Supply chain integration and steady gross margins already above 70% strengthen the case for margin progression as the business scales.

• Analysts’ consensus view notes that sustainable margin expansion is tied to successfully entering the U.S. market. Positive pivotal trial data and FDA Fast Track Designation could open a market three times larger than its current core:

  • The company’s addressable patient pool grows if regulatory milestones are hit in the U.S. and pediatric indications expand within Europe.

  • Consensus sees market penetration and improved margins as achievable, but only if execution matches the ambitious entry and adoption plan for new geographies.

• What is surprising is that despite the lack of accelerating profit growth so far, the clinical advantages and hospital investment trends identified in the consensus narrative are expected to maintain or lift margins further.

• Sedana trades at a Price-to-Sales ratio of 5.4x, above its peer average of 2.9x but nearly identical to the Swedish Medical Equipment industry average of 5.5x. This shows that while it looks relatively expensive versus direct peers, its valuation closely mirrors the wider sector.

• According to analysts’ consensus, this valuation profile places Sedana in line with industry momentum. Continued strong revenue growth could justify the premium if margin trends hold:

  • Analysts expect 23.3% annual revenue growth over the next three years, far surpassing the Swedish market’s 3.9% rate.

  • Even so, consensus argues that reaching fair value depends on both revenue delivery and eventual profitability, metrics not yet achieved as the company plans for U.S. launch and ongoing expansion.

• The consensus outlook suggests that Sedana’s share price of 10.6 sits well below the analyst price target of 21.0. This reinforces how valuation tension is influenced by forward growth assumptions and execution risk.